@mah7925
Keytruda is effective for some cancers and for others the results are not so great. For endometrial cancer the overall survival difference for non PDL-1 cancer is only 6 months between the group that got Keytruda and the group that did not. To me that is a low efficacy for that cancer as it is not a cure and only prolongs survival with the added danger of side effects occurring.
I feel like they massage the data to come up with the greatest sounding benefits and downplay any potential negative side effects. I see for kidney cancer after 4 years the survival rate is 6% higher for those who are on Keytruda vs no treatment after surgery, (91% vs 86%), but that 21% of those getting treatment had to drop out due to side effects. That seems like a high rate of side effects to me. Hopefully someone will come up with a drug that does not over activate the immune system so severely.